<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04944628</url>
  </required_header>
  <id_info>
    <org_study_id>Normocolic ADL</org_study_id>
    <nct_id>NCT04944628</nct_id>
  </id_info>
  <brief_title>Observational Prospective Study With Probiotic Supplementation on Infants With FGDI</brief_title>
  <official_title>An Observational Prospective Study to Evaluate the Efficacy of 2 Weeks of Oral Supplementation With a Probiotic Formula in Infants With Functional Gastrointestinal Disorders (FGDI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AB Biotics, SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AB Biotics, SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This observational prospective study evaluates the safety, tolerability and efficacy of a&#xD;
      probiotic formula in infants with functional gastrointestinal disorders (FGDI)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Functional gastrointestinal disorders (FGDIs) affect one out of two infants during the fist&#xD;
      six months of life and do not have an organic cause. Infant colic, so-called excessive crying&#xD;
      syndrome, and functional constipation are among the most common paediatric FGDIs.&#xD;
&#xD;
      FGDIs pathophysiology is multifactorial and may include phycological factors and alterations&#xD;
      of the gut physiology including gut microbiota dysbiosis.&#xD;
&#xD;
      Probiotics are proposed as a potential treatment for FGDIs. However, evidence is limited.&#xD;
&#xD;
      A probiotic formula composed of strains Bifidobacerium longum CECT 7894 and Pediococcus&#xD;
      pentosaceus CECT 8330 is tested in this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 15, 2018</start_date>
  <completion_date type="Actual">December 5, 2018</completion_date>
  <primary_completion_date type="Actual">December 5, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in total FGDI severity</measure>
    <time_frame>Day 1 and day 14</time_frame>
    <description>FGDI severity measured as summatory of excessive crying score (5-point Likert scale (0: no symptoms, to 4: extremely severe symptoms) + constipation score (5-point Likert scales (0: no symptoms, to 4: extremely severe symptoms)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in excessive crying severity</measure>
    <time_frame>Day 1 and day 14</time_frame>
    <description>Excessive crying score measured using 5-point Likert scales (0: no symptoms, to 4: extremely severe symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in constipation severity</measure>
    <time_frame>Day 1 and day 14</time_frame>
    <description>Constipation score measured using 5-point Likert scales (0: no symptoms, to 4: extremely severe symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in parental anxiety</measure>
    <time_frame>Day 1 and day 14</time_frame>
    <description>Recorded through the validated Generalized Anxiety Disorder (GAD) 7-item scale (GAD-7).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability and safety</measure>
    <time_frame>Daily from day 1 to day 14</time_frame>
    <description>Any adverse events experienced throughout study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parental satisfaction with the product</measure>
    <time_frame>Day 14</time_frame>
    <description>Measured with a 5-point Likert scale (0: very dissatisfied, to 4: very satisfied)</description>
  </secondary_outcome>
  <enrollment type="Actual">36</enrollment>
  <condition>Functional Gastrointestinal Disorders</condition>
  <condition>Infantile Colic</condition>
  <condition>Functional Constipation</condition>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic</intervention_name>
    <description>Probiotic in liquid format (oil suspension) administered 10 drops once daily for 2 weeks (2x10^9 cfu/day)</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Population selected from primary care clinic.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with gastrointestinal symptoms related to FGID including functional&#xD;
             constipation and/or infant colic diagnosed according to Rome IV criteria for clinical&#xD;
             purposes.&#xD;
&#xD;
          -  ≥ 37 weeks of gestation at birth.&#xD;
&#xD;
          -  ≥ 2500 g of birth weight.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Infants with failure to thrive (weight gain &lt;100 grams/week on average from birth).&#xD;
&#xD;
          -  Major medical problems (e. g. immunodeficiencies, developmental problems or genetic&#xD;
             abnormalities)&#xD;
&#xD;
          -  Gastrointestinal diseases&#xD;
&#xD;
          -  Administered with antibiotics for 4 weeks or probiotics for 2 weeks before or during&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>10 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maura Sticco, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Sanitaria Locale Napoli</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Azienda Sanitaria Locale Napoli</name>
      <address>
        <city>Naples</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006 May 22;166(10):1092-7.</citation>
    <PMID>16717171</PMID>
  </reference>
  <reference>
    <citation>Benninga MA, Faure C, Hyman PE, St James Roberts I, Schechter NL, Nurko S. Childhood Functional Gastrointestinal Disorders: Neonate/Toddler. Gastroenterology. 2016 Feb 15. pii: S0016-5085(16)00182-7. doi: 10.1053/j.gastro.2016.02.016. [Epub ahead of print]</citation>
    <PMID>27144631</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 14, 2021</study_first_submitted>
  <study_first_submitted_qc>June 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2021</study_first_posted>
  <last_update_submitted>June 21, 2021</last_update_submitted>
  <last_update_submitted_qc>June 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FGDI</keyword>
  <keyword>probiotic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Diseases</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
    <mesh_term>Colic</mesh_term>
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

